A veterinary sedative is showing up in the illicit fentanyl supply across the United States, and the CDC has issued an urgent warning: naloxone, the medication that reverses opioid overdoses, does not work against it.
The drug is called medetomidine — also known on the street as "rhino tranq," "mede," or "dex." When it is mixed with fentanyl, it can cause profound sedation, dangerously low blood pressure, and a slow heart rate that persist even after naloxone has been administered. For anyone carrying naloxone to respond to a potential overdose — or administering it to a family member — understanding this limitation is now a matter of life and death.
The CDC and the White House Office of National Drug Control Policy (ONDCP) issued a joint Health Alert Network advisory on April 2, 2026, warning that detections of medetomidine in illicit drug seizures increased by 950 percent from 2023 to 2024, then rose an additional 215 percent in 2025.
Why This Matters
Naloxone has been one of the most effective tools in reducing opioid overdose deaths over the past decade. The expansion of naloxone access — through pharmacies, community programs, emergency responders, and now over-the-counter availability — has saved tens of thousands of lives.
But naloxone works by blocking opioid receptors. It has no mechanism of action against medetomidine, which operates through a completely different pathway: alpha-2 adrenergic receptors. When medetomidine is present alongside fentanyl, a person who receives naloxone and appears to briefly improve may relapse into dangerous sedation as the naloxone wears off — while the medetomidine continues to act.
Dr. Brian Hurley, medical director of substance abuse prevention and control at the Los Angeles County Department of Public Health, described the risk directly: "Naloxone doesn't address medetomidine intoxication, nor does it touch medetomidine withdrawal. So that's why people will need other supportive care."
What We Know So Far
According to the CDC's Health Alert Network advisory, medetomidine was first detected in the illicit drug supply in 2021 and began appearing regularly with fentanyl in Chicago, Philadelphia, and Pittsburgh from mid-2023 onward. By late July 2024, it had been detected in at least 18 states and the District of Columbia.
The detection numbers tell a stark story: medetomidine reports in the National Forensic Laboratory Information System rose from 247 in 2023 to 2,616 in 2024 — a 950 percent increase — and then to 8,233 in 2025, a further 215 percent jump. The drug is most concentrated in the Northeast (52 percent of reports) and Midwest.
In New York City, medetomidine was listed as a contributing cause in 134 fatal overdoses in 2025, up from 18 in 2024 — a more than sevenfold increase in a single year.
Where the Risk Is Highest
The Northeast and Midwest carry the heaviest burden of documented medetomidine exposure. New York, Philadelphia, Chicago, Pittsburgh, and the surrounding metro areas have seen the highest detection rates in drug seizures and wastewater samples.
However, the White House and CDC advisory notes that the geographic spread is expanding. Anyone in a community where illicit fentanyl is present should be aware that medetomidine may be present as well, even without a local announcement.
People who use drugs, their families, friends, neighbors, and anyone who has been trained to respond to overdoses with naloxone need to understand that naloxone alone may not be enough when medetomidine is involved.
What Doctors and Experts Say
The CDC's clinical guidance makes the treatment hierarchy clear: administer naloxone first, because fentanyl is present in most medetomidine-positive samples and naloxone will restore breathing impaired by the opioid. Then call 911 immediately, because medetomidine sedation will persist beyond what naloxone can address.
The CDC advises clinicians to suspect medetomidine when a patient has prolonged sedation after naloxone administration. A slow heart rate (bradycardia) during overdose and rapid heart rate (tachycardia) with high blood pressure during apparent recovery can help distinguish medetomidine toxicity from standard opioid overdose presentation.
Toxicologists should be consulted, and comprehensive drug screening, including medetomidine in blood (preferred) and urine, should be ordered for patients presenting with suspected drug overdoses who do not respond to naloxone as expected.
The ONDCP's Director of National Drug Control Policy Sara Carter stated: "The public health community, as well as those who put themselves at risk of overdose due to illegal drug use, need to be aware of ever-evolving dangers."
What the Evidence Shows — and What It Does Not
The pharmacology of medetomidine is well understood: it is an alpha-2 adrenergic agonist used in veterinary medicine to sedate animals (particularly for rhinoceros sedation, which explains the street name "rhino tranq"). Its mechanism is completely distinct from opioids, which is why naloxone has no effect on it.
What is less certain is the precise mortality contribution of medetomidine in individual overdose deaths, because forensic testing for it was rare until recently. The dramatic increase in detected deaths in New York is likely a combination of true increase and improved detection — but both factors point in the same dangerous direction.
The CDC notes that medetomidine reports comprised less than 1 percent of all NFLIS drug reports in 2025 — but the rate of increase suggests this proportion will grow.
Who Faces the Greatest Risk?
- People who use illicit fentanyl in any form, particularly in the Northeast and Midwest
- People who have regular exposure to medetomidine and then stop abruptly — including after naloxone reversal — who may experience severe withdrawal with dangerous cardiovascular symptoms
- First responders and bystanders who administer naloxone and assume recovery is complete, not realizing medetomidine sedation continues
- Family members of people who use drugs who carry naloxone as a precautionary measure
Symptoms and Warning Signs to Watch For
Signs of medetomidine intoxication include:
- Profound, deep sedation that does not improve after naloxone
- Very slow heart rate (bradycardia)
- Low blood pressure (hypotension)
- Pinpoint pupils
Signs of medetomidine withdrawal (which may occur when naloxone reverses opioid effects and medetomidine is present) include:
- Rapid heart rate (tachycardia)
- Severely elevated blood pressure
- Fluctuating alertness and agitation
- Tremors
- Chest pain
- Intractable nausea and vomiting
Both states — intoxication and withdrawal — can cause organ damage and death without medical support beyond what naloxone provides.
What You Can Do Now
- If you carry naloxone or have a family member who uses drugs, understand that naloxone is still the right first step in any suspected overdose. Administer it — then call 911 immediately regardless of whether the person appears to respond.
- Do not assume recovery is complete after naloxone. Stay with the person and monitor until emergency medical responders arrive.
- If you live in a community where medetomidine is known to be present, ask your local health department or harm reduction program about fentanyl and medetomidine test strips. Test strips can detect medetomidine in drug samples before use.
- For clinicians: consider medetomidine in any overdose patient with prolonged sedation after naloxone and consult a toxicologist or call Poison Control at 1-800-222-1222.
- Local and state health departments can contact the CDC for laboratory support and guidance.
Cost and Access: What Patients Should Know
Naloxone remains essential and is now available over the counter at most U.S. pharmacies. It is covered without a prescription. However, because medetomidine cannot be reversed by naloxone, people in communities where this drug is present need emergency medical care — not just naloxone — for a complete overdose response. The HRSA Substance Use Warmline offers free confidential clinical consultation at 844-275-6222, Monday through Friday, 7 a.m. to 5 p.m. Pacific Time.
What Happens Next
The CDC's Overdose Data to Action (OD2A) program is supporting state and local health departments in expanding medetomidine surveillance. Wastewater testing for medetomidine is expected to expand through 2026 to provide earlier geographic warning signals. MedicalDaily will continue tracking medetomidine spread and any changes to the CDC's overdose response guidance.
The Bottom Line
Medetomidine is spreading through the illicit fentanyl supply, and it cannot be reversed by naloxone. Naloxone is still essential and should still be given first — but calling 911 immediately after administering it is now critical, even if the person appears to respond. Prolonged sedation, slow heart rate, and low blood pressure after naloxone administration are warning signs that medetomidine may be involved. This is a dangerous new development in the overdose crisis, and every person who carries naloxone needs to know about it.
References
- CDC HAN — Medetomidine in the U.S. Illegal Fentanyl Supply (April 2, 2026)
- CDC — Medetomidine Situation Summary
- White House ONDCP — Health Advisory on Medetomidine in Illicit Fentanyl (April 6, 2026)
- ABC7 Los Angeles — CDC Issues Warning About "Rhino Tranq"
- Hoodline — Medetomidine Surge Hits New York's Illicit Fentanyl Supply
- Healio — CDC Warns of Medetomidine in Illicit Drugs
